Examkin

Question

Difficulty: HardInfectious Diseases

Match each clinical presentation of infective endocarditis or severe bacteremia to its most appropriate targeted antimicrobial regimen.

  • Prosthetic aortic valve (placed 3 months ago) endocarditis growing methicillin-resistant Staphylococcus epidermidis (MRSE)Intravenous vancomycin, rifampin, and gentamicin
  • Native mitral valve endocarditis growing Enterococcus faecalis in a patient with stage 3 chronic kidney diseaseIntravenous ampicillin and ceftriaxone
  • Native tricuspid valve endocarditis growing methicillin-susceptible Staphylococcus aureus (MSSA) currently on empiric vancomycinIntravenous cefazolin
  • Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with a rapidly rising serum creatinine on day 4 of vancomycin therapyIntravenous daptomycin

Answer

Prosthetic valve MRSE matches with Vancomycin/Rifampin/Gentamicin. E. faecalis with CKD matches with Ampicillin/Ceftriaxone. MSSA matches with Cefazolin. MRSA with nephrotoxicity matches with Daptomycin.
Each correct pairing aligns with infectious disease guidelines: staphylococcal prosthetic valves require rifampin and gentamicin adjuncts; MSSA strictly requires beta-lactam de-escalation; enterococcal endocarditis with renal impairment requires aminoglycoside-sparing dual beta-lactams; and vancomycin-induced nephrotoxicity necessitates a switch to daptomycin.

Step-by-Step Solution

1
Analyze the prosthetic valve endocarditis case (MRSE).
Identify the need for biofilm penetration.
Staphylococcal infections of prosthetic material develop robust biofilms. Rifampin is required to penetrate the biofilm, but it cannot be used alone due to rapid resistance. It must be combined with vancomycin (for MRSE) and gentamicin (for early synergy).
2
Analyze the E. faecalis endocarditis case with chronic kidney disease.
Select a synergistic regimen that spares the kidneys.
Enterococcal endocarditis requires synergy. While ampicillin plus gentamicin is traditional, ampicillin plus ceftriaxone achieves synergy through dual penicillin-binding protein inhibition and completely avoids nephrotoxic aminoglycosides.
3
Evaluate the MSSA endocarditis case on empiric vancomycin.
Determine the optimal definitive therapy.
Vancomycin is inferior to anti-staphylococcal penicillins (nafcillin) or first-generation cephalosporins (cefazolin) for MSSA. Standard antimicrobial stewardship dictates de-escalation to cefazolin.
4
Assess the MRSA bacteremia case complicated by acute kidney injury.
Choose a bactericidal agent active against MRSA with a different toxicity profile.
Vancomycin is notoriously nephrotoxic. Daptomycin is highly bactericidal against MRSA and is not nephrotoxic, making it the ideal switch when acute kidney injury occurs.

Key Concept

Targeted antimicrobial therapy for bacteremia and endocarditis requires adjustment based on pathogen susceptibility (e.g., MRSA vs. MSSA), infection site (prosthetic biofilm vs. native valve), and patient-specific toxicities (nephrotoxicity).
Rate this question

Topics

Infectious Diseases

More questions from this topic